David Hough

2021038, Dec 16, 2021

Dec 18, 2018

16/956403

- Titusville NJ, US
Wayne Drevets - San Diego CA, US
Honglan Li - Pennington NJ, US
David Wood Hough - Pennington NJ, US
Adam Janik - San Diego CA, US
Rachel Ochs-Ross - Pennington NJ, US
Jaskaran Singh - San Diego CA, US
Ewa Wajs - Beerse, BE
Peter Zannikos - Titusville NJ, US

A61K 31/135
A61K 9/00
A61P 25/24

The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

2013033, Dec 12, 2013

May 28, 2013

13/903638

- Beerse, BE
Srihari Gopal - Belle Mead NJ, US
David W. Hough - Wallingford PA, US
Bart M. M. Remmerie - Gent, BE
Mahesh N. Samtani - Flemington NJ, US

Janssen Pharmaceutica NV - Beerse

A61K 31/519
A61K 9/00

51425941

The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides a method for treating psychiatric patients in need of a switching treatment to paliperidone palmitate in a sustained release formulation.

6261522, Jul 17, 2001

Oct 13, 1998

9/170271

David Hough - Edwardsburg MI
Willis E. Howard - Elkhart IN
Richard Hurtle - Elkhart IN
Gary E. Rehm - Elkhart IN

Bayer Corporation - Elkhart IN

G01N 2113
G01N 3502

422 8205

An apparatus for automatically detecting the presence of a reagent strip (14) having a body fluid sample disposed thereon and for inspecting the reagent strip (14) after the presence of the reagent strip (14) is detected is provided with a detection system adapted to automatically detect the presence of a reagent strip (14) at a reagent strip receiving area (12), a light source (64 or 68) adapted to illuminate the reagent strip (14) after the presence of the reagent strip (14) at the reagent strip receiving area (12) is detected, and a detector (66 or 70) adapted to receive light from the reagent strip (14) when the reagent strip (14) is being illuminated by the light source. The detection system is provided with a light emitting apparatus (30) adapted to illuminate the reagent strip receiving area (12), a detecting apparatus (32) adapted to receive light from the reagent strip receiving area (12) while the reagent strip receiving area (12) is being illuminated by the light emitting apparatus (30) and to generate a detection signal relating to the amount of light detected from the reagent strip receiving area (12), and a circuit (120 or 144, 148) adapted to automatically determine whether a reagent strip (14) is present at the reagent strip receiving area (12) based on the magnitude of the detection signal.

2013010, Apr 25, 2013

Oct 18, 2012

13/654496

David M. Hough - Rochester MN, US
Lifeng Yu - Inver Grove Heights MN, US
Joel G. Fletcher - Oronoco MN, US
Cynthia H. McCollough - Byron MN, US

A61B 6/03

378 8

A system and method for acquiring an image of a region of interest (ROI) of subject using a computed tomography (CT) system includes a) performing a scout scan of the subject using the CT system to yield scout data related to the ROI and b) determining an initial contrast volume form at least the scout data. The method also includes c) prescribing a scanning protocol to be implemented using the computed tomography system to image the ROI and d) determining a size of the subject about the ROI. The method further includes e) determining a computed tomography dose related to volume (CTDIvol) based on at least the size determined at step d) and f) adjusting the scanning protocol prescribed in step b) to match at least one of a desired radiation dose and a relative intravenous (IV) contrast dose to a reference CTDIvol. The method includes g) acquiring imaging data from the ROI using the CT system by using the adjusted scanning protocol.

2011010, May 5, 2011

Nov 1, 2010

12/916910

Srihari Gopal - Belle Meade NJ, US
David W. Hough - Wallingford PA, US
Bart M.M. Remmerie - Gent, BE
Mahesh N. Samtani - Flemington NJ, US

A61K 31/519
A61P 25/18

51425941

The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides a method for treating psychiatric patients in need of a switching treatment to paliperidone palmitate in a sustained release formulation.

4526568, Jul 2, 1985

Sep 29, 1982

6/426983

A. H. Clemens - Elkhart IN
David L. Hough - Edwardsburg MI

Miles Laboratories, Inc. - Elkhart IN

A61M 500
A61B 500

604 4

A diagnostic apparatus and method for clamping the blood glucose concentration of a subject at any one of a plurality of levels. A desired clamping level (BC) is selected and the value of the present blood glucose concentration, corrected to fit a least squares regression lines (GY) in the bloodstream of the subject is periodically determined. Dextrose is introduced into the bloodstream of the subject at a rate (DR) derived in accordance with ##EQU1## wherein: DR=dextrose infusion rate for clamp (mg/min) WT=body weight (kg) BC=desired clamp level (mg %) GY=present blood glucose level, corrected to fit a least squares regression line (mg %) M=slope of the least squares regression line fit for the last five glucose values KS=constant to allow adjustment for differences in metabolism ##EQU2## (Glucose utilization in mg/kg/min).

4464170, Aug 7, 1984

Sep 29, 1982

6/428381

A. H. Clemens - Elkhart IN
David L. Hough - Edwardsburg MI

Miles Laboratories, Inc. - Elkhart IN

A61M 500

604 50

In a method and apparatus for controlling the concentration of glucose in the blood stream of a subject at a desired level (BI) including controlling the supply of insulin (IR) by periodically measuring the blood glucose concentration (G) and selecting a predetermined basal infusion rate (RI) for the desired level, the step of selecting a predetermined basal infusion rate comprises periodically searching for the value of the basal infusion rate RI required for BI in accordance with RI=RI. sub. LAST (GY/BI) where (GY) is the present blood glucose level corrected to fit a least squares regression line, when the slope of the least squares regression line fit for the last five G values is less than 0. 5 and GY is within. +-. 50% of the desired BI level, and wherein the period between searches is equal to or greater than the period between glucose measurements.

5165078, Nov 17, 1992

Mar 25, 1991

7/674458

David L. Hough - Edwardsburg MI
Willis E. Howard - Elkhart IN
Donald L. Jaworski - South Bend IN

Miles Inc. - Elkhart IN

G02B 2602

359233

A radiation aperture system where two sets of apertures are distributed in ring sections of like radius on two parallel rings. As one ring is rotated with respect to its counterpart, one aperture of each ring will align to pass a radiation beam through both apertures. Only a single aperture pair is formed at each unique time, allowing sequential measurements of all combinations of both aperture openings during rotation without halting the rotation.